Although the cardiometabolic-renal benefits of new drug classes like SGLT2 inhibitors, GLP-1 receptor analogues, or dual agonists appear to be present in both sexes [78], they are less often prescribed in women even if treatment is recommended according to guidelines because of concomitent heart failure, cardiovascular disease, or chronic kidney disease [79]. This evidence concerns the gene SLC5A2 and heart failure.